- Home
- ECO vs URGN Comparison
ECO vs URGN Comparison
Compare ECO & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECO | URGN |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 922.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ECO | URGN |
|---|---|---|
| Price | $40.33 | $21.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $37.00 | $29.50 |
| AVG Volume (30 Days) | 447.8K | ★ 799.3K |
| Earning Date | 02-18-2026 | 03-09-2026 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $349,886,578.00 | $96,516,000.00 |
| Revenue This Year | N/A | $26.47 |
| Revenue Next Year | $5.10 | $110.65 |
| P/E Ratio | $20.48 | ★ N/A |
| Revenue Growth | N/A | ★ 8.00 |
| 52 Week Low | $17.91 | $3.42 |
| 52 Week High | $41.31 | $30.00 |
Technical Indicators
Market Signals| Indicator | ECO | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 49.03 |
| Support Level | $38.38 | $19.13 |
| Resistance Level | $41.22 | $22.21 |
| Average True Range (ATR) | 1.02 | 1.27 |
| MACD | -0.13 | 0.15 |
| Stochastic Oscillator | 57.25 | 65.44 |
Price Performance
Historical ComparisonAbout ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.